Jade Biosciences, Inc. (JBIO) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$15.01

From 52W high−45.18%

Volume223723.00

Market cap$936.15M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$15.01

From 52W high

−45.18%

Volume

223723.00

Market cap

$936.15M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.0x

P/E (TTM)

—

RSI (14)

46.0

MomentumView details →

1D Return

+1.03%

YTD Return

−6.34%

SummaryUpdated Jun 1, 2026

Jade Biosciences, Inc. (NASDAQ:JBIO) is a clinical-stage biotechnology company founded to develop innovative therapies for autoimmune diseases. The company went public in April 2025 and is headquartered in the United States. Jade Biosciences focuses specifically on addressing critical unmet medical needs in autoimmune conditions, with its lead program targeting a rare kidney disease called IgA nephropathy.

Ask drillr about Jade Biosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−34.83%

ROA (TTM)

−32.46%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+82.69%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+95.24%

EBITDA YoY

—

MomentumView details →

1D Return

+1.03%

YTD Return

−6.34%

1Y Return

+60.58%

RSI (14)

46.0

vs 50D SMA

−10.81%

vs 200D SMA

−20.75%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

14.93x

Quick Ratio

14.93x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.76

EPS Surprise

−19.42%

Beats (12Q)

3/12

Next Q EPS Est

−$0.75

Avg Surprise (4Q)

15.58%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−153.24M

Op. CF (TTM)

−123.51M

Next earningsNov 12, 2026 →

Latest newsMore news →

Jade Biosciences announced preclinical data characterizing JADE301, a half-life-extended anti-IFN-β monoclonal antibody in development for dermatomyositis, at EADV 2026.35d ago

Similar companies

MoonLake ImmunotherapeuticsMLTX Inventiva S.A.IVA Savara Inc.SVRA Rigel Pharmaceuticals, Inc.RIGL ORIC Pharmaceuticals, Inc.ORIC Sunho Biologics, Inc.02898.HK Find similar companies →

Latest newsMore news →

Jade Biosciences, Inc. announced that three JADE101 posters will be presented at ASN Kidney Week 2026, including an updated expectation that the EVERGREEN Phase 3 trial will begin in the fourth quarter of 2026.14d ago Jade Biosciences announced preclinical data characterizing JADE301, a half-life-extended anti-IFN-β monoclonal antibody in development for dermatomyositis, at EADV 2026.35d ago